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ABSTRACT 
OBJECTIVES: 
 To find out the incidence rate of head and neck malignancies in  
males, females  and the symptoms with which the patient present, along 
with their stage of presentation. Lifestyle and habits of patients examined 
to identify risk factors. Identification of neck secondaries, 
histopathological types and selection of best treatment option are other 
objectives of this study.      
METHODS: 
 Prospective analysis of 150 patients with newly diagnosed 
malignancies of nasopharynx, oropharynx, larynx, hypopharynx and ear 
from June 2009 to November  2011. 
RESULTS: 
 Most  malignancies common in patients greater than 40 years of 
age. 88% of cancer occur in males. Oropharynx cancer is the most  
common cancer in our study, with the commonest subsite as base of 
tongue growth. Supraglottic and pyriform fossa tumours are the 
commonest tumour in laryngeal and hypopharyngeal cancers. The most 
common presentation is dysphagia. Synergistic effect of smoking and 
alcohol is seen in 50% of patients. Almost  all cancers seen in stage III 
and IV except glottis cancer which is predominantly seen in  
stage I. Almost all cases are squamous cell carcinoma.                
CONCLUSION: 
 The results of the study are almost similar to many other head and 
neck malignancies study in various parts of the world. Supraglottic is the 
common laryngeal tumour as opposed to glottis in certain western 
studies. Analysis of various factors helped in early diagnosis and 
management which helped in increasing the survival rate of patients.                               
KEYWORDS: 
 Incidence. oropharynx. hypopharynx. larynx. nasopharynx. 
Malignancy. smoking. alcohol. squamous cell carcinoma. Dysphagia. 
neck secondaries. 
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INTRODUCTION 
 The  rate of  ENT malignancies is growing  day by day. It 
contributes to a total of 10% among all malignancies reported with a 
mortality rate of more than 50% in a period of 5 years in Chennai alone.  
 Madras Metropolitan Tumour Registry1, a population based cancer 
registry in Chennai states that as of 2006 – 2008 study, carcinoma 
oropharynx, hypopharynx and larynx are amongst the top 10 cancers in 
males. The crude incidence rate (CIR) of oropharynx, hypopharynx and 
larynx  is  6.2, 4.0 and 3.6 respectively (as of 2008 period).  Cancers are 
more common in the age group of  35 – 64 years in both male and female. 
 It is continuously  rising  with the ever increasing  risk factors. 
ENT malignancies are one which can be diagnosed  clinically to a great 
extent when compared to others. The  secondaries  in  neck  are  one of  
the  major  presenting symptoms. The study of the ENT malignancies and 
neck secondaries give us an idea about the prevalence rate of neck 
secondaries associated with ENT malignancies.  
 Choosing the correct line of management and predicting the 
favourable prognosis is of paramount importance to increase the survival 
rate. This dissertation  analysis the  incidence  of  ENT  malignancies 
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(Nasopharynx, Oropharynx, Larynx, Hypopharynx , Ear)  in  various  
aspects like  male – female sex ratio, role of smoking, alcohol and other 
risk factors, presenting  symptoms, sites and subsite  of  tumours, stage of  
presentation, histological type and treatment modality  undertaken.  This  
dissertation  analysis  a total of 150 cases from June 2009 – November 
2011.  
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AIMS AND OBJECTIVES 
1. To collect the data about the cases recorded with ENT 
malignancies over the period of my study. 
2.  To find out the incidence rate in males and females and the 
symptoms with which the patients present, along with their 
stage of presentation. 
3.  To examine the lifestyle and habits of these people in order to 
identify the risk factors and etiopathogenesis of these 
malignancies. 
4.  To find out the neck secondaries as a presentation in various 
malignancies. 
5.  To find different histopathological types and differentiation. 
6.  To select the best treatment option for the patient, according to 
their stage of presentation by means of policy taken in tumour 
board. 
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MATERIALS AND METHODS 
Study design:  Prospective study 
Study place:  Department of ENT, Kilpauk Medical College and 
Government Royappettah Hospital, Chennai. 
Study period:  June 2009 – November 2011 
Sample size: 150 patients 
- Written informed consent obtained from all participating subjects. 
Privacy will be ensured. 
-  A thorough clinical examination of the patients was done by 
means of a questionnaire format.  
- The whole information will be compiled. Statistical analysis will 
be done by using a statistical software. 
INCLUSION CRITERIA: 
 All  patients attending ENT department in Kilpauk medical college 
& Hospital and Government Royappetah Hospital, Chennai who are 
newly diagnosed with ENT malignancies such as nasopharyngeal 
 
   
5 
 
tumours, oropharyngeal tumours, laryngeal tumours, hypopharyngeal, ear 
tumours.  
EXCLUSION CRITERIA: 
1. Children (0  - 12 years age group) 
2. Patients with poor general condition 
3. Patients who are not suitable for any kind of cancer treatment. 
4. Patients who were previously treated or undergoing treatment 
or recurrent cases. 
5. Patients with other head and neck cancers . 
TECHNIQUES: 
1. Detailed history is collected. 
2.  Primary data were gathered via tick box and interviews. The 
following data will be gathered. 
i. Patients age and sex 
ii. Habits 
- Smoker/Non smoker 
- Tobacco chewing 
- Alcohol consumption 
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- Pan chewing / Betal nut 
                  iii. General questions 
   -  Diet 
   - Symptoms 
   - Awareness etc.. 
        iv. Histopathological type of malignancies 
        v. At what stage where they diagnosed 
        vi. What treatment they are having 
3. A thorough clinical examination is done.  
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REVIEW OF LITERATURE 
HISTORICAL REVIEW: 
1. Broders (1920)Æ four tiered grading system for proportion of 
highly differentiated cells within entire neoplasm. 
2. Rouviere’s (1932)Æ described ten lymph node  of head and neck 
cancer. This form the base of today naomenclature. 
3. Jussawalla (1973) , IndiaÆ conducted study which suggested 
tobacco as a risk factor for hypopharyngeal cancer. 
4. Larsson , Sandstrom, and Westlins(1975)Æ showed that iron 
deficiency associated with postcricoid carcinoma, especially in 
patients with plummer Vinson syndrome.  
5. Batsakis (1979) proved a strong association between cigarette 
smoking and carcinoma larynx. 
6. Batsakis(1979)Æ great majority of hypopharyngeal tumours are 
poorly differentiated . 
7. Neumen and Byers (1982) recorded the peak incidence of age 
between 5th and 6th decade in laryngeal malignancies. 
8. Study conducted by Royal Morsden Hospital between 1983 and 
1991 showed that  out of 127 patients, 73 patients are of tonsillar 
growth, 42 patients are of base of tongue, 8 patients soft palate and 
4 patients posterior pharyngeal wall. 
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9. Chi and Kahyo (1991), korea suggested that synergistic effect of 
tobacco and alcohol as a risk factor for hypopharyngeal cancer. 
10.  Jones(1992)Æ 20% of hypopharyngeal tumours are well 
differentiated. 
11.  Cummings et al (1996) showed various factors causing malignant 
tumours of larynx and hypopharynx. 
12.  Danish population study of 28,180 people(recent study)Æ  
association between different alcoholic drinks and aerodigestive 
cancers. They said subject who drank 7 – 21 units per week of beer 
(or) spints, but no wine had a relative risk of 3.0 of developing 
oropharyngeal (or) nasopharyngeal cancer. 
13.  Lydiatt (recently) said that the the disadvantage of TNM system is 
that they are not intuitive and would require a chart for most 
clinicians to stage their patients. The site of stage grouping is 
small, preventing accurate prediction from previous experience. 
14.  Fisch and Del Buona – used in vivo lymphangiograph to delineate 
clinically relevant lymph node groups. Their observation 
contributed to the development of currently used neck staging 
system of the Memorial Sloan – Kettering cancer centre, which 
divides the neck into 6 levels.( levels I to VI) 
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TUMOURS OF  NASOPHARYNX 
ANATOMY  OF  NASOPHARYNX 9 
 Anterior wall: Choana and Nasal septum 
 Floor:  Soft palate 
 Lateral wall:  Eustachian tube  and  fossa of  Rosenmuller 
 Roof:  Basisphenoid and Basiocciput. Occupied by adenoids and 
mergers with posterior wall of pharynx. 
EPIDEMIOLOGY OF NASOPHARYNGEAL CANCER 
 Incidence in US and Europe is only about 1/1, 00,000, but in 
Taiwan, Hongkong and China the incidence is approximately 30 times 
higher17. More common in males (M:F:2:1). Incidence peaks about 50 – 
60 years of age. Among low risk population it has a bimodal presentation 
i.e. between 10 – 20 years and later at about 55 – 65 years of age. Genetic 
analysis revealed that association of HLA A2, HLA B17 and HLA BW26 
doubles the risk, especially in endemic population.  Other risk factors are  
EBV infection, chronic nasal infections, poor hygiene, poor ventilation 
and exposure to nitrosoamines  in salt preserved foods4. Active and 
passive smoking have not been conclusively proven as risk factors in high 
risk population3.  
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 In India, it is uncommon and constitutes only 0.41% (0.66% in 
males and 0.17% in females) of all cancers except in Northeast region 
where people are predominantly of Mongoloid origin.  
PATHOLOGY 
 Most cases are  squamous cell carcinomas (85%). 
WHO classification9 
 Type 1 (25%) - Keratinsing squamous  cell carcinoma 
Type 2 (12%) - Non keratinsing carcinoma ( with and without 
lymphoid stroma) 
Type 3 (63%) - Undifferentiated carcinoma (with and without 
lymphoid stroma) 
 Squamous cell carcinoma is further divided into well differentiated, 
moderately differentiated and poorly differentiated tumours.  
 Grossly,  tumour presents in three forms: 
1. Proliferative 
2. Ulcerative 
3. Infiltrative 
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CLINICAL  FEATURES 
1. Nasal 
¾ Nasal obstruction 
¾  Nasal discharge 
¾  Rhinolalia clausa 
¾ Epistaxis 
2. Otologic 
¾ Conductive hearing loss 
¾  Tinnitus 
¾ Dizziness 
 Unilateral serous otitis media in an adult should arise suspicion of 
nasopharyngeal growth.  
3. Ophthalmoneurologic 
Nearly all cranial nerves may be involved. 
¾ Squint and  Diplopia (VI th nerve) 
¾  Opthalmoplegia (III, IV, VI) 
¾  Facial pain and reduced corneal reflex (V th nerve) 
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¾  Orbital apex involvement leading to exophthalmos 
and blindness (II nd nerve) 
¾  Jugular foramen syndrome( IX , X & XI th cranial 
nerves) 
¾  Hypoglossal canal involvement (XII th nerve) 
¾  Horners syndrome( cervical symphathetic chain 
involvement) 
TROTTERS TRAID 
 Conductive deafness, ipsilateral temporoparietal neuralgia and 
palatal paralysis.  
4. Cervical Nodal Metastasis (60 – 90 %) 
¾ Most common presentation 
¾  May be the only manifestation of Nasopharyngeal 
cancer 
¾  When first seen, 50% are with bilateral nodes 
5. Distant Metastasis 
¾ Involves bone, lung, liver and other sites 
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STAGING  (TNM)3 
T  STAGING 
 T1 Æ Tumour confined to nasopharynx 
 T2 a Æ Tumour extends to soft tissues of oropharynx and/ or oral 
cavity without parapharyngeal extension. 
 T2 b Æ Tumour extends to soft tissues with parapharyngeal 
extension. 
 T3 Æ Tumour invades bony structures and / or paranasal sinuses 
 T4Æ Tumour with intracranial involvement and/ or involvement of 
cranial nerves, hypopharynx, orbit (or) masticator space. 
Parapharyngeal extension denotes posterolateral infiltration of tumour 
beyond the pharyngo - basilar fascia.  
N  STAGING 
 NxÆ Regional lymph nodes cannot be assessed.  
 N0Æ No regional lymph node metastasis 
 N1Æ Unilateral metasatasis in lymph nodes 6 cm (or) less in 
greatest dimension, above the supraclavicular  fossa. 
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 N2Æ Bilateral metastasis in lymph nodes 6cm (or) less in greatest 
dimension, above the supraclavicular fossa 
 N3 a Æ Metastasis in lymph nodes greater than 6cm in dimension. 
 N3 bÆ Metastasis in lymph nodes in the supraclavicular fossa. 
STAGE  GROUPING2,5,10,12  (different from other head and neck 
cancer) 
Stage T N M 
0 Tis N0 M0 
1 T1 N0 M0 
II a T2a N0 M0 
II b 
T1 
T2a 
T2 b 
N1 
N1 
N0,N1 
M0 
M0 
M0 
III 
T1 
T2a,T2b 
T3 
N2 
N2 
N0,N1,N2 
M0 
M0 
M0 
IV a T4 N0,N1,N2 M0 
IV b ANY T N3 M0 
IV c ANY T ANY N M1 
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DIAGNOSIS 
 Based primarily on history and physical examination4. Definite 
diagnosis with biopsy. Preferred imaging modalities are CT scan with 
contrast and MRI with enhancement. 
TREATMENT 
 Megavoltage external radiotherapy (MERT) is the primary 
treatment modality of choice3. 
 Stage I and IIÆ Conventional Radiotherapy 
 Stage III and IV BÆ Radiotherapy + Chemotherapy 
 Salvage Treatment 
a. For local disease – surgery 
b. For neck disease - Radical neck dissection 
SURGICAL APPROACHES TO NASOPHARYNX5 
1. ANTERIOR APPROACHES 
i. Lateral Rhinotomy 
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ii. Transnasal transmaxillary 
iii. Midfacial degloving 
iv. Lefort I osteotomy 
v. Maxillary swing procedure 
2. INFERIOR APPROACHES 
i. Transpalatal 
ii. Mandibular swing 
3. Lateral (or) infratemporal approach 
LYMPHATIC DRAINAGE 
- Drain into upper deep cervical nodes either directly or indirectly 
through retropharyngeal or parapharyngeal lymph nodes. They also 
drain into spinal accessory chain of nodes in the posterior triangle 
of neck. Lymphatics  may also cross midline to drain  into  
contralateral lymph nodes. 
DIVISION OF NECK NODES ACCORDING TO LEVELS9 
Level 1  -  Submental (IA) 
       Submandibular (IB)
  
 
 
 
LEVELS OF NECK NODES 
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Level 2  -  Upper jugular 
Level 3  -  Mid jugular 
Level 4  -  Lower jugular 
Level 5  -  Posterior triangle group 
   (spinal accessory and transverse cervical  
   chains) 
Level 6  -  Prelaryngeal 
      Pretracheal 
      Paratracheal 
Level 7  -  Nodes of  upper  mediastinum 
- This division is according to Memorial Sloan Kettering cancer 
centre 
TUMOURS OF OROPHARYNX 
ANATOMY OF OROPHARYNX 
 Extends from the level of hard palate superiorly to the level of 
hyoid bone inferiorly. 
BOUNDARIES9 
Anterior wall:
 
 
  
 
 
ANATOMY OF OROPHARYNX 
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¾ Base of tongue 
¾ Vallecula 
¾ Lingual  surface of epiglottis 
Lateral wall:  Medial wall of  parapharyngeal  space 
¾ Anterior pillar  ( palatoglossus) 
¾  Posterior pillar (palatopharyngeus) 
¾ Palatine tonsil 
Roof:  
¾  Soft palate (containing two heads of palatopharyngeus 
muscle) 
¾  Levator palati 
¾  Tensor palati 
¾  Palatoglossus 
  Posterior wall: 
 Extends from the level of soft palate to the level of hyoid bone and 
is anterior to C2 and C3 vertebra. This consists of superior and middle 
constrictors and the bucco pharyngeal fascia, which separates it from  
prevertebral  fascia. 
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EPIDEMIOLOGY  OF  OROPHARYNGEAL  CANCER12  
 Worldwide, approximately 3, 90,000 new cancer of oral and 
oropharynx were diagnosed annually. The incidences of these tumours 
are particularly high in South central Asia, South Africa and Europe8. In 
the USA, the incidence of oral and pharyngeal cancer is 11.9/ 1, 00,000 
population per year with approximately 30,000 new cases per year. 
 Males are three times more commonly affected than females.  
Among males, the highest rates are in blacks, followed by whites 
(especially Non- Hispanics), Vietnamese and native Hawaiians8,9. 
Incidence increase in 30 – 54 and 55- 69 year old group.  
 In India, it is quite common due to the increased usage of betal nut 
and pan parag along with excessive smoking and alcohol consumption. It 
is the most common cause of head and neck malignancy in India along 
with oral cavity.  
RISK FACTORS 
1. Tobacco and alcohol are the most common etiologic factors 
associated with squamous cell carcinoma of  oropharynx. 
Compared with persons who never smoked, smokers have an 
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increased relative risk  of  2.7 for 1 to 20 cigarettes per day and 9.0 
for more than 20 cigarettes per day. Cigarettes have higher tar 
content. Regarding alcohol consumption, relative risk increases 
steadily with amount of alcohol consumed, 1.2 for 1 to 4 drinks per 
week and 3.3 for 15 to 29 drinks per week and 8.8 for more than 30 
drinks per week.  
2. Betel nut chewing increase the risk especially in developing 
countries. Consumption of fruits and vegetables reduces the risk for 
cancer from one third to one half. 
3.  Presence of Human Papilloma Virus(HPV type 8 , 16) is 
considered a risk factor for Squamous cell carcinoma of tonsil. 
Recently, one study states that  HPV infected men had longer  
survival than HPV negative men. 
4.  Other factors: Ionizing radiation, iron deficiency anaemia, dental 
submucous fibrosis of palatine arch9. 
TUMOUR TYPES 
- Most common is squamous cell carcinoma (90%),  
- Others are Non Hodgkins (8%) and minor salivary gland tumours 
(2%). 
- In squamous cell carcinoma, the most common sites are 
¾ Lateral wall (60%) 
¾ Anterior wall, mainly base of tongue (25%) 
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¾ Soft palate (10%) 
¾ Posterior wall (5%) 
- 90% of  lymphomas occur in the lateral wall (or) tongue base9. 
- Minor salivary gland tumours mostly occurred in soft palate. 
STAGING (TNM)10,2 
T  STAGING2,6 
 T1 Æ Tumour 2cm (or) less in greatest dimension. 
T2  Æ  Tumour  more than 2cm but not more than 4cm in greatest 
dimension. 
 T3 Æ Tumour  more than 4 cm in greatest dimension. 
 T4 aÆ Tumour invades any of the following: deep extrinsic 
muscles of the tongue ( genioglossus , hyoglossus, palatoglossus , 
styloglossus), larynx, medial pterygoid , mandible and hard palate. 
 T4 bÆ Tumour invades any of the following: lateral pterygoid 
muscle, pterygoid plates, lateral nasopharynx, skull base (or) encasement 
of  the carotid artery. 
N  STAGING 
 NxÆ Regional lymph nodes cannot be assessed. 
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 N0Æ  No regional lymph node metastasis. 
 N1Æ Metastasis in a single ipsilateral lymph node 3 cm (or) less in 
greatest dimension. 
 N2aÆ Metastasis in a single ipsilateral lymph node involvement 
more than 3cm, but not more than 6cm in greatest dimension. 
 N2 bÆ Metastasis in  multiple  ipsilateral  lymph node, more than 
3cm, but not more than 6cm in greatest dimension. 
 N2 cÆ Metastasis in  bilateral (or) contralateral  nodes, none more 
than 6cm in greatest dimension. 
N3Æ Metastasis in a lymph node more than 6cm in greatest 
dimension. 
STAGE GROUPING5,10,12 
STAGE T N M 
0 T1 N0 M0 
I T1 N0 M0 
II T2 N0 M0 
III T1,T2 N1 M0 
IV a T1,T2,T3 T4a 
N2 
N0,N1,N2 
M0 
M0 
IV b ANY T T4b 
N3 
ANY N 
M0 
M0 
IV c ANY T ANY N M1 
 
 
23 
 
PRESENTING FACTORS 
1. Sore throat 
2. Otalgia 
3. Dysphagia 
4. Ulcer 
5. Pain 
6.  Trismus 
7. Neck mass 
TREATMENT PROTOCOL 
1. Carcinoma  of the tonsil (or) lateral wall13 
Stage I, II and some stage III (T1-2,N1) – External beam RT 
Stage III, IV – surgery followed by RT 
2. Carcinoma  of  tongue base 
Stage I, II – RT (or) surgery 
Stage III, IV – If surgery- wide resection with major 
reconstruction 
   Alternative treatment – ChemoRT 
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3. Soft palate tumours 
Stage I, II – surgical excision (or) EBRT (or) Brachytherapy 
Stage III, IV – RT (or) combined treatment 
4. Posterior pharyngeal wall  
Most are advanced when diagnosed. 
Treatment options include RT alone (or) surgical resection 
with (or) without neck dissection. 
SURGICAL APPROACHES 
1. Transoral approach 
a. Oral approach 
b. Lip – splitting approach without mandibulotomy 
2. Transoral / Transcervical combined approach 
a. Lingual mandibular  release 
3. Transpharyngeal 
 a.  Suprahyoid   pharyngotomy 
 b. Lateral pharyngotomy 
  4. Transmandibular 
   a. Mandibulotomy 
    b. Mandibullectomy 
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TUMOURS   OF  LARYNX 
ANATOMY OF LARYNX 
 
 It consists of  3 regions –  supraglottis , glottis and subglottis. Each 
region is anatomically and embryologically distinct with separate 
lymphatic channels.  
1. Supraglottis 
¾ Suprahyoid epiglottis ( including lip, lingual and 
laryngeal surfaces) 
¾ Aryepiglottic fold, laryngeal aspect 
¾ Arytenoid 
¾ Infrahyoid epiglottis 
¾ Ventricular bands (False cords) 
2. Glottis 
¾  Vocal cords 
¾ Anterior commissure 
¾ Posterior commissure 
3.Subglottis 
  
ANATOMY OF LARYNX 
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EPIDEMIOLOGY OF LARYNGEAL CANCER5,16 
 Laryngeal cancer is the most common head and neck cancer 
worldwide. Incidence is highest in report from South America and the 
countries surrounding the Mediterranean, while the lowest reported in 
Finland. Glottis tumours predominate in The Anglo – Saxons, while the 
Africo Carribean, Indian sub continent and French population have equal 
cases of glottis and subglottic growth. Most common age at presentation 
is 7th decade and most common in male.  
 In India, larynx constitutes 2% of all head and neck malignancies. 
It is 10 times more common in males than females (4.79%  vs  0.47%) its 
incidence is 3.29 new cases in males and 0.42 new cases in females per 
1,00,000 population, according to National Cancer Registry, ICMR, April 
2005. 
RISK FACTORS18,19,21,22 
1. Tobacco  and Alcohol 
 Tobacco acts via polycyclic hydrocarbon like benzopyrene, whose 
products bind directly to DNA and RNA. 
 Alcohol promote carcinogenesis through  acetaldehyde exposure , 
malnutrition and dessilation of mucosa.  
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2. HPV -  16 
3. Exposure to asbestos, formaldehydeand therapeutic radiation. 
4. Diet and Vitamin (A and C)  deficiency. 
5. Premalignant conditions like laryngeal keratosis and 
leucoplakia 
CLASSIFICATION  OF  LARYNGEAL TUMOURS 
1. Epithelial  
a . Squamous cell carcinoma (MC) 
b. Verrcuous carcinoma 
c. Spindle cell carcinoma 
2.   Non epithelial 
      a. Adenoid cystic carcinoma 
      b.  Malignant  histiocytoma 
      c. Osteosarcoma 
     d. Neurooendocine carcinoma 
     e. Fibrosarcoma 
    f. Chondrosarcoma 
 
 
 
28 
 
3. Lymphoproliferative tumours 
  a. Lymphoma 
  b. Melanoma 
 4. Metastatic  lesion 
  a. Breast, kidney 
  b.  Melanoma 
Mostly the tumours are well differentiated squamous cell carcinoma. 
PRESENTING  FEATURES 
1. Progressive hoarseness 
2. Breathing difficulty and stridor 
3. Pain 
4. Dysphagia 
5. Swelling in neck 
STAGING   (TNM) 
T  STAGING 
1. SUPRAGLOTTIS2,10,12,31 
T1Æ tumour limited to one subsite of supraglottis with vocal 
cord mobility. 
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T2Æ tumour invades mucosa of more than one adjacent 
subsite of supraglottis (or) glottis (or) region outside the 
supraglottis. (eg. : mucosa of base of tongue, vallecula, 
medial wall of pyriform sinus) without fixation of larynx. 
T3Æ Tumour limited to larynx with vocal cord fixation and 
invades any of the following: postcricoid area, pre epiglottic 
tissues, paraglottic space and/or with minor thyroid cartilage 
erosion.(eg.: inner cortex) 
T4 aÆ tumour invades through thyroid cartlage and / or 
invades tissues beyond the larynx, eg. Trachea, soft tissues 
of the neck, including deep / extrinsic muscle of the tongue 
(genioglossus, hygoglossus, palatoglossus and styloglossus) 
strap muscles, thyroid and oesophagus. 
T4bÆ Tumour invades prevertebral space, mediastinal 
structures or encases carotid artery. 
 
 
30 
 
2. GLOTTIS10,12,5 
T1 aÆ tumour limited to one vocal cord. (may involve anterior or 
posterior commissure) with normal mobility. 
T1 b Æ tumour limited to both vocal cords. (may involve anterior 
or posterior commissure) with normal mobility. 
T2Æ tumour extends to supraglottis  and / or  subglottis , and / or 
with impaired vocal cord mobility. 
T3Æ tumour limited to larynx with vocal cord  fixation and / or 
invades paraglottic space, and / or with minor thyroid cartilage 
erosion(inner cortex) 
T4 aÆ tumour invades through cartilage or invades tissues beyond 
the larynx. Eg. Trachea, soft tissues of neck including deep 
extrinsic muscles of  tongue. (genioglossus, hyoglossus, 
palatoglossus and styloglossus) strap muscles, thyroid and 
oesophagus. 
T4bÆ Tumour invades prevertebral space, mediastinal structures 
or encases carotid artery. 
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3. SUBGLOTTIS5,12 
T1Æ Tumour limited to subglottis 
 T2Æ Tumour extends to vocal cord(s) with normal or 
 impaired mobility. 
T3Æ  Tumour limited to larynx with vocal cord fixation 
T4 aÆ tumour invades through cartilage or invades tissues 
beyond the larynx. Eg. Trachea, soft tissues of neck including deep 
extrinsic muscles of  tongue. (genioglossus, hyoglossus, 
palatoglossus and styloglossus) strap muscles, thyroid and 
oesophagus. 
T4bÆ Tumour invades prevertebral space, mediastinal 
structures or encases carotid artery. 
N staging and stage grouping similar to oropharyngeal tumours. 
TREATMENT   PROTOCOL 
1. For insitu carcinoma: 
Vocal cord stripping can be done. Frequent followup and repeat 
biopsy 6 to 12 weeks later if needed. 
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2. For T1 and T2 leison: 
Radiotherapy is the treatment of choice. 
3. For T3 and T4 tumours: 
Total laryngectomy with neck dissection followed by post 
OP RT 
4. For residual (or) recurrent (or) resistant tumours following RT 
Æ Total laryngectomy 
CONSERVATIVE LARYNGEAL SURGERIES 
Criteria: 
1. Young patients(<60yrs) with a good pulmonary reserve 
2. Tumour should be limited to the larynx and preferably one 
arytenoids should be free of tumour. 
3.  Laryngeal spaces should be free of disease. 
4. Preferably unirradiated  neck 
Types: 
1. Vertical partial hemilaryngectomy 
2. Horizontal partial hemilaryngectomy( supraglottic 
hemilaryngectomy) 
3. Subtotal laryngectomy 
4. Near total laryngectomy 
 
 
33 
 
 
 
TUMOURS  OF  HYPOPHARYNX 
ANATOMY OF HYPOPHARYNX 
 It is a highly important anatomical site, since  physiologically a 
component of upper aerodigestive tract and in its upper part, it represents 
conduit for both respiration and degluttion. 
LYMPHATIC DRAINAGE 
 Pyriform fossa  - 75%(5% bilateral)- mainly levels2,3 
 Post cricoids - 20%(5% bilateral)- paratracheal nodes 
Posterior pharyngeal wall – 50% Æ Retropharyngeal and upper 
deep cervical. 
EPIDEMIOLOGY OF HYPOPHARYNGEAL CANCER5 
 Rare  tumours. Otherwise called  “ extrinsic laryngeal tumours”. 
Tumours present in late stages. Poorest prognosis for any head and neck 
cancer. Incidence  is 1 in 1,00,000. Mostly seen in male >45 years except 
post cricoid carcinoma common in young females. Post cricoid carcinoma 
has wide geographical variation in its frequency. 
 ANATOMY OF HYPOPHARYNX 
 
INDIRECT LARYNGOSCOPY EXAMINATION 
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 In India, hypopharyngeal tumours are more common than laryngeal 
tumours, as compared to western world due to the increasing incidence of 
smoking and alcohol consumption  and various nutritional 
deficiencies.25,27,28  
SITEWISE DISTRIBUTION 
1. Pyriform sinus – 60% 
2. Post cricoid – 30% 
3. Posterior pharyngeal wall – 10% 
RISK FACTORS 
1. Smoking and alcohol 
2. Low intake of fruits and vegetables 
3. Diet deficiency in vitamin C, E and PUFA, Zinc 
4. Exposure to welding fumes, polycyclic aromatic hydrocarbons 
5. Radiation exposure – for thyroid cancer 
6. Post cricoids carcinoma in patients with iron deficiency 
7. Association with lung cancer (RR Æ2 : 3) 
8. Association with HPV16,18. 
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TYPES OF HYPOPHARYNGEAL CANCER5,29 
         Almost all are squamous cell carcinomas. 
1. Squamous cell carcinomas Æ 70% well differentiated (or) 
moderately differentiated. 
2. Non squamous tumours and carcinomas (3.5%) Æ Benign 
(<1%) 
3. Carcinoma in situ 
4. Lymphoma 
5. Small cell neuroendocrine 
6. Adenoid cystic 
7. Adenocarcinoma 
8. Transitional cell 
9. Malignant fibrous histiocytoma 
10. Undifferentiated 
11. Metastases 
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CLINICAL PRESENTATION 
1. Persistent and progressive Dysphagia – may not be present in 
posterior pharyngeal wall tumour. 
2. Referred otalgia 
3. Throat pain 
4. Hoarseness of voice 
5. Neck mass 
6. Hemoptysis 
7. Weight loss 
8. Chest symptoms 
9. Aspiration 
STAGING (TNM)5,10,12 
T  STAGING 
 T1Æ Tumour limited to one subsite of hypopharynx and 2cm or 
less in greatest dimension. 
 T2Æ Tumour invades more than one subsite of hypopharynx or an 
adjacent site , or measures 2 – 4 cm in greatest dimension, without 
fixation of hemilarynx. 
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T3Æ Tumour invades more than  4 cm in greatest dimension, or 
with  fixation of  hemilarynx. 
T4 aÆ Tumour invades any of the following : thyroid/ cricoid 
cartilage, hyoid bone, thyroid gland, oesophagus, central compartment of 
soft tissue. 
T4 bÆ Tumour invades prevertebral fascia, encases carotid artery 
or invades mediastinal structures. 
N staging and stage grouping similar to oropharynx and larynx. 
TREATMENT 
 Stage I , II Æ Primary RT (or) surgery 
 Stage III , IVÆ Surgery and Post OP RT 
SURGERIES FOR PYRIFORM SINUS TUMOURS32 
1. Partial laryngopharyngectomy 
2. Total pharyngectomy with partial pharyngectomy 
3. Total laryngectomywith pharyngeal reconstruction 
SURGERIES FOR POST CRICOIDS CARCINOMA: 
1. Total pharyngolaryngectomy with free jejunal transfer. 
 
 
38 
 
2. Total pharyngolaryngooesophagectomy with gastric 
transposition 
POSTERIOR PHARYNGEAL WALL TUMOUR 
1. Lateral pharyngotomy and primary repair ( or) laser / diathermy 
excision. 
2. Lateral transhyoid ( or) midline suprahyoid pharyngectomy. 
3. Total pharyngolaryngectomy with reconstruction. 
INVESTIGATIONS  
1. Routine blood and  urine examination 
2. X ray chest PA view – to look for secondaries and GA fitness 
3. X ray soft tissue AP and lateral view – to look for subglottic air 
column and widening of prevertebral soft tissue. 
4. X ray  Barium swallow 
5. Rigid (or) flexible scopy (Pan endoscopy) 
a. Diagnostic nasal endoscopy 
b. Nasopharyngoscopy 
c. Videolaryngoscopy 
d. Direct laryngoscopy 
e. Microlaryngoscopy 
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6. FNAC 
7. Biopsy 
8. CT scan neck 
9. CT scan PNS – for nasopharyngeal carcinoma extent 
10. CT SCAN OF CHEST AND LIVER Æ TO RULE OUT 
METASTASIS 
11. MRI 
12. PET 
13. SPECT 
TUMOURS  OF  EAR 
1. Tumours of  external auditory canal: 
Aetiology of  EAC  tumours: 
a. Chronic inflammation 
b.  Irradiation injury 
c.  Azoxymethane – induces squamous cell 
carcinoma of sebaccous glands of ear. 
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Types: 
 90% are squamous cell carcinomas. Mostly arise from bony EAC. 
Slow growing and 20% of tumours have cervical lymphadenopathy. 
Other tumours : 
a. Adenocarcinoma 
b. Mucoepidermoid carcinoma 
c. Adenoid cystic carcinoma 
d. Malignant melanoma 
e. Sebaccous cyst carcinoma 
2. Tumours of middle ear :  
Incidence: 
 In UK, 1 per million per year for women and 0.8 per million per 
year for men.  Male : female ratio is 1: 1.2.  
Aetiology: 
a. Preexisting chronic otitis media (85%) 
b. Irradiation induced. 
Types: 
 Mostly, squamous cell carcinoma. It causes extensive bony 
destruction and nerve involvement. Lymphadenopathy seen in 10 – 15 % 
at presentation .  Adenocarcinoma  rare and seen in females. 
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Staging for carcinoma of ear: 9,2 
 Neither UICC nor AICC has developed staging system for 
carcinoma of ear. 
T1  - Tumour  limited to the site of origin, no facial nerve 
paralysis and no bone destruction.  
T2  - Tumour extending beyond  the site of origin, indicated 
by facial paralysis or radiological evidence of bone 
destruction, but no extension beyond the organ of origin. 
T3  - Clinical or radiological evidence of extension to 
surrounding structures ( dura, base of the skull, parotid 
gland, temperomandibular joint, etc.) 
T4  - Patients with insufficient  data for classification, 
including patients previously seen and treated elsewhere.  
Î In both tumours, syrgery is the treatment of choice. 
Î Punch biopsy  under local (or) general anaesthesia is the 
diagnostic procedure of choice.  
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RESULTS 
The various results of my study are as follows: 
AGE WISE DISTRIBUTION 
AGE NASO ORO LARYNX HYPO 
<20  3 0 0 0 
21 – 40 1 4 2 4 
41 – 60 2 35 17 19 
61 – 80 1 27 17 16 
>80 0 1 0 0 
  
 
 
  
 
 
 
 
 
 
 
  
 
NASOPHARYNGEAL CARCINOMA 
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From my study  I compared the age distribution of 150 patients 
with respect to five ENT malignancies. The youngest patient – a 14 year 
old  male with nasopharyngeal carcinoma and the oldest patient – a 83 
year old male with CA tonsil.  
 The highest incidence  of carcinoma for the  respective age 
intervals. 
  Nasopharyngeal carcinoma is common in < 20 years and 41 – 60 
years age group. Oropharyngeal, Larngeal and Hypopharyngeal 
carcinoma are common in patients > 40 years of age.  One patient 
diagnosed with CA middle ear was a 44 year male.  
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SEX WISE DISTRIBUTION 
SEX NASO ORO LARYNX HYPO 
MALE 5 60 32 42 
FEMALE 2 7 4 7 
 
 
 
 
 
  
 
 In my study 130 patients are male and 20 patients are female which 
accounts for 88% of  cancer incidence in males. All carcinomas are 
common in males except post cricoid carcinoma where out of 9 cases, 6 
cases occurred in females.  
 
 
 
 
45 
 
SITE WISE DISTRIBUTION 
SITEWISE 
DISTRIBUTION NO.OF.CASES PERCENTAGE
NASOPHARYNX 7 4% 
OROPHARYNX 67 45% 
LARYNX 36 24% 
HYPOPHARYNX 39 26% 
 
 
 In my entire study oropharynx topped with 45% of cases, followed 
by hypopharynx, larynx and nasopharynx. There was only one case of 
carcinoma middle ear. 
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SUBSITE DISTRIBUTION OF OROPHARYNX 
SITES NO.OF.CASES PERCENTAGE
LATERAL WALL 23 33% 
ANTERIOR WALL 48 61% 
SOFT PALATE 4 6% 
 
 
 
 
 
 
 From the above pie chart, it can be seen that the commonest site 
affected in oropharyngeal tumours is Anterior wall, followed by lateral 
wall and soft palate tumours. In the anterior wall tumours 51% are 
tumours involving posterior one – third or base of the tongue, 10% are 
tumours involving vallecula. In lateral wall tumours out of 33% , 31% are 
seen involving tonsil, followed by 2%  of anterior pillar growth. In my 
study there was no case of posterior oropharyngeal growth.
  
 
 
 
 
CANCER OF BASE OF TONGUE 
 
 
 
 
 
 
 
  
 
 
 
 
CARCINOMA RIGHT TONSIL 
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SUBSITE DISTRIBUTION OF LARYNX 
SITES NO.OF.CASES PERCENTAGE
SUPRAGLOTTIS 18 50% 
GLOTTIS 16 44% 
SUBGLOTTIS 2 6% 
 
 
 
 
 
 
 The pie chart depicts the subsite distribution of  laryngeal 
malignancies. Out of  36 cases of larynx, 50% cases are seen in 
supraglottis followed by glottis and subglottis.  
 
 
 
 
 
 
 
CANCER RIGHT VOCAL CORD 
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 In supraglottic tumours the most commonly seen subsite is 
Aryepiglottic fold (10 cases), followed by Arytenoid (3 cases), Infrahyoid 
epiglottis (3 cases), suprahyoidepiglottis (2 cases) . there  was no case of 
carcinoma arising in ventricular band or sinus region. In  glottic tumours , 
all the cases are  vocal cord carcinomas. There was no primary tumour 
involving only the anterior commissure or only the posterior commissure 
in this series. I have encountered 2 cases of subglottic growth with 
extension to vocal cords. 
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SUBSITE DISTRIBUTION OF HYPOPHARYNX 
SITES NO.OF.CASES PERCENTAGE 
PF 25 64% 
PC 9 23% 
PP 5 13% 
 
 
 
 
 
 
 
 Most common hypopharyngeal tumour is pyriform sinus, followed 
by post cricoid and posterior pharyngeal wall.  
  
 
CANCER RIGHT PYRIFORM SINUS 
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CLINICAL PRESENTATIONS 
CLINICAL 
PRESENTATIONS NASO ORO 
LAR/
SUP 
LAR 
/GLOT 
LAR/ 
SUB 
HYPO/ 
PF 
HYP
O/PC 
HYP
O/PP 
SWAL DIFF. 0 25 3 0 0 6 4 1 
SWAL DIFF., 
BREATH  DIFF. 
0 3 1 0 0 0 2 0 
SWAL 
DIFF.,BREATH  
DIFF.,NS 
0 2 1 1 0 1 0 0 
SWAL 
DIFF.,BREATH  
DIFF.,CHANGE IN 
VOICE 
0 3 3 1 1 4 0 0 
SWAL 
DIFF.,BREATH  
DIFF.,CHANGE IN 
VOICE,NS 
0 0 0 0 0 2 0 0 
SWAL 
DIFF.,BREATH  
DIFF./STR 
0 0 0 1 0 0 1 0 
SWAL 
DIFF.,BREATH  
DIFF./STR,CHANGE 
IN VOICE 
0 0 2 2 1 1 0 0 
SWAL 
DIFF.,BREATH  
DIFF./STR,CHANGE 
IN VOICE,NS 
0 1 0 0 0 0 0 0 
SWAL DIFF.,NS 0 10 0 0 0 1 0 0 
SWAL 
DIFF.,CHANGE IN 
VOICE 
0 13 4 0 0 5 1 2 
SWAL 
DIFF.,CHANGE IN 
VOICE,NS 
0 5 0 0 0 2 1 0 
BREATH  DIFF. 0 1 0 0 0 0 0 0 
BREATH  DIFF.,NS 0 1 0 0 0 0 0 0 
BREATH  
DIFF.,CHANGE IN 
VOICE 
0 0 0 2 0 2 0 0 
BREATH  
DIFF./STR,CHANGE 
IN VOICE 
0 0 2 0 0 0 0 0 
NS 3 2 1 0 0 1 0 0 
CHANGE IN VOICE 1 0 1 9 0 0 0 0 
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 From the above chart it is seen that most patients presents with 
Dysphagia. Nasopharyngeal carcinoma patients presented with neck 
swelling, nasal symptoms like blood stained discharge, nasal obstruction, 
frank epistaxis. Oropharyngeal , supraglottic and hypopharyngeal 
malignancies mostly presented with dysphagia.  Change of voice more 
commonly seen in glottic tumours and the 2 case of subglottic tumour  in 
our study presented with stridor. 
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RISK FACTORS 
RISK 
FACTORS 
NASO ORO LAR/
SUP 
LAR/ 
GLOT 
LAR/ 
SUB 
HYPO/
PF 
HYPO/ 
PC 
HYPO/
PP 
S+A-  0 15 5 1 1 3 0 0 
S+A-,OR-
BETAL 
0 1 0 0 0 0 0 0 
S+A+  1 32 9 11 1 18 2 4 
S+A+,OR-
BETAL 
0 1 0 0 0 0 0 0 
S+A+,OR-
PAN 
0 5 0 0 0 2 0 0 
S-A- 6 8 1 3 0 2 5 1 
S-A-,OR-
BETAL 
0 2 2 0 0 0 2 0 
S-A+,OR-
PAN 
0 1 0 0 0 0 0 0 
S-A+ 0 1 0 1 0 0 0 0 
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 In my study, synergistic effect of smoking and alcohol seen in 
almost 57% of patients. Smoking alone as an independent  risk  factor 
seen in 26%  but alcohol as an independent risk factor seen in just 3 
cases. Post cricoid carcinoma patients (7 female cases)are not associated 
with risk factors of smoking and alcohol.Betal nut and pan parag usage as 
an independent risk factor is seen in very few patients. 
STAGE OF PRESENTATION 
STAGES NASO ORO LAR/
SUP 
LAR/ 
GLOT 
LAR/
SUB 
HYPO/
PF 
HYPO/ 
PC 
HYPO/ 
PP 
I 0 2 1 10 0 0 1 0
II 2 8 0 1 0 0 0 2
III 4 25 9 4 0 5 6 2
IV 1 32 8 1 2 20 2 1
 STAGES OF PRESENTATION
0
5
10
15
20
25
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35
SUP GLOT SUB PF PC PP
NASO ORO LAR/ LAR/ LAR/ HYPO/ HYPO/ HYPO/
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F 
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T
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N
T
S
I
II
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 Almost all cancers in our study are seen in stage 3 and 4 except 
glottic cancer involving vocal cord which is predominantly seen in stage 
1.In our study, early glottis cancer patients are subjected to curative 
radiotherapy treatment and they responded well.Surgery (TLN WITH 
POST OP RT) done for 2 patients who are ideal candidates.Most patients 
rejected surgery and opted for CHEMORT,eventhough they are ideal 
candidates. 
T STAGE 
STAGES NASO ORO LAR/ SUP 
LAR/ 
GLOT 
LAR/ 
SUB 
HYPO/
PF 
HYPO/ 
PC 
HYP/ 
PP 
T1 1 6 2 11 0 1 1 0 
T2 2 8 0 1 0 0 0 2 
T3 4 25 9 4 0 5 6 2 
T4 1 32 8 1 2 20 2 1 
 
T - STAGES
0
5
10
15
20
25
30
35
SUP GLOT SUB PF PC PP
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 As seen in the above table and bar diagram ,most patients presented 
with T3 and T4 growth especially pyriform sinus tumours ,where most of 
the patients presented in stage 4.11 cases of glottic  cancer presented in 
T1 stage. 
N  STAGING 
STAGES NASO ORO LAR/ 
SUP 
LAR/ 
GLOT 
LAR/ 
SUB 
HYPO/ 
PF 
HYPO/ 
PC 
HYPO/
PP 
N0 1 18 11 16 1 7 5 5 
N1 4 20 4 0 1 2 3 0 
N2 2 22 2 0 0 10 1 0 
N3 7 0 1 0 0 6 0 0 
 N - STAGING 
0
5
10
15
20
25
SUP GLOT SUB PF PC PP
NASO ORO LAR/ LAR/ LAR/ HYPO/ HYPO/ HYPO/
SITES & SUBSITES
N
O
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T
IE
N
T
S
N0
N1
N2
N3
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 In my study,64 cases(43%)presented without neck secondaries. All 
glottis patients presented with no neck secondaries . Surprisingly 11 out 
of 18 supraglottic cancers presented with no neck secondaries, 
eventhough their T staging is mostly T3 or T4.Mostly the patients with 
neck secondaries presented in N2 stage,except nasopharyngeal cancer 
presenting with N3 mostly. 
HISTOLOGICAL PRESENTATION  
HISTOLOGY NASO ORO LAR/
SUP 
LAR/
GLOT 
LAR/
SUB 
HYPO/
PF 
HYPO/ 
PC 
HYPO/
PP 
WDSCC 2 18 1 9 1 4 3 3 
MDSCC 2 39 13 5 1 17 6 1 
PDSCC 0 7 4 2 0 3 0 1 
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Adeno carcinoma -  CA base of the tongue (1 case) 
Diffuse large B cell lymphoma – CA tonsil (1 case) 
Low grade mucoepidermoid carcinoma – CA tonsil (1 case) 
Non keratinsing SCC – CA nasopharynx (1 case) 
Undifferentiated carcinoma – CA nasopharynx (2 cases) 
Small round cell tumour – CA pyriform sinus (1 case) 
 In my 2.5 years of  study I found that squamous cell carcinoma 
(95%) as the most common type of  cancer.  Only 5% of cases are non 
squamous tumours.Mostly the tumours are moderately differentiated 
except glottis carcinoma which is predominantly well differentiated.  
 We have only one case of carcinoma ear, involving middle ear. 
Patient is a 44 year old male with chronic history of ear pain, ear 
discharge and hard of hearing. Patient presented in stage II and the biopsy 
report is well differentiated squamous cell carcinoma. 
 In my study period, I have seen only these 5 malignancies in our 
hospital. We have not come across other head and neck malignancies.  
 
 
 
 
 
TOTAL LARYNGECTOMY PATIENT (POST OP PICTURE) 
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DISCUSSION 
 In this section I have compared important results of my study with 
previous National and International studies. Mostly I have drawn 
comparison with statistical data from Madras Metropolitan Tumour 
Registry,1 National cancer Registry program, ICMR, who documented 
cancer incidence and mortality in Chennai, India from the year  
2006 – 2008. 
I. PEAK AGE INCIDENCE 
STUDY NASO ORO LAR HYPO 
MMTR 20 – 40 &40 
– 60 
40 – 60 60 – 80 60 – 80 
Present 
Study 
<20 & 
40 - 60 
40 – 60 40 – 60 & 
60 – 80 
40 – 60 
 
 In both the studies , there is bimodal distribution of nasopharyngeal 
carcinoma. However in my study, the first peak is < 20 years as compared 
to 20 – 40 years in MMTR. In my study, patients with laryngeal and  
hypopharyngeal malignancies presented predominantly in 40 – 60 years 
of age group as compared to a relatively younger age group in  MMTR.  
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 In Ray Chowdury’s study on topographical distribution of 
laryngeal carcinoma in 50 patients (published in Indian Journal of 
Otolaryngology and head and neck surgery, Dec 2002). laryngeal 
carcinoma occurred commonly in 40 – 60 years age group.  
II. SEX WISE DISTRIBUTION  
STUDY ORO LAR HYPO 
MMTR 
     M                   
     F 
 
89% 
11% 
 
88% 
12% 
 
71% 
29% 
Present Study 
     M 
    F 
 
 
90% 
10% 
 
 
89% 
11% 
 
 
82% 
18% 
  
 In nasopharyngeal carcinoma, the male female ratio is 2.4 : 1 
whereas in a study conducted by John kong Sangwoo and Andrew van 
Hasselt, male female ratio is 3:1.  
 In Ray Chowdury’s study( 1997), male female ratio in laryngeal 
carcinoma is 16: 1, whereas in our study male female ratio is 8:1. In 
Ahmedin Jemal, Rebecca siegel, cancer statistics(2007) study, male 
female ratio in larynx is 4:134. 
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 In our study, in oropharyngeal cancer male female ratio is 3:1, 
whereas 8:1 in MMTR study and  2:1 in cancer statistics (2007) study and 
Nationwise study of epidemiology of oropharyngeal cancer in 
Netherlands, Mak kregar, Hilgers(1995)35. 
 In our study, male female ratio is 4.6:1 in hypopharyngeal 
malignancy, whereas 3:1 in MMTR study and 1.7:1 in Pingree and 
KimDavis study. 
SUBSITE DISTRIBUTION 
OROPHARYNX 
Study Base Of 
Tongue 
Tonsil Vallecula Soft 
Palate 
Others 
MMTR 40% 23% 3% 10% 24% 
Present 
Study 
51% 31% 10% 6% 2% 
Mac Kregar 
Study(1995) 
28% 
(includes 
vallecula) 
58% -  10% 4% 
  
 In Mac Kregar and Hilgers study, 28%  involves both base of 
tongue and vallecula growth. There is 4% of posterior oropharyngeal wall 
growth cases in this study. However in our present study, we found no 
cases of posterior oropharyngeal wall. Tonsil is the most common site of 
involvement in Mac Kregar study, whereas in MMTR and our study base 
of tongue growth is the commonest oropharyngeal subsite.  
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LARYNX 
STUDY SUPRA- 
GLOTTIS 
VOCAL 
CORD 
SUBGLOTTIS NOS
MMTR 34% 38% 1% 27% 
Present Study 50% 44% 6% - 
Lederman(1952) 25% 61% 12% - 
Powel & 
Robin(1983) 
19% 76% 5% - 
Thawley(1991) 40% 59% 1% - 
Chakraborty(1992) 78% 13% 4% 5% 
Ray Chowdury’s 
study(1995) 
58% 40% 2% - 
 
 In Indian studies like MMTR, Chakraborty, Ray Chowdury and our 
study, the most common laryngeal cancer is Supraglottis, whereas in 
Lederman, Powel & Robin and Thawley study, the most common 
laryngeal cancer is glottis involving vocal cords. In our study, 
aryepiglottic  fold is the most common subsite as in the case of Powel & 
Robin study. The demerit of Lederman’s study is  that, he considered 
suprahyoid epiglottis, AE folds and arytenoids as a part of hypopharynx.  
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HYPOPHARYNX 
STUDY PYRIFORM 
SINUS 
POST 
CRICOID
POSTERIOR 
PHARYNGEAL 
WALL 
NOS 
MMTR 41% 26% 1% 32% 
Present 
Study 
64% 23% 13% - 
Jones & 
Stell 
Liverpool 
study series 
45% 40% 8% - 
  
 In all above 3 studies commonest site for hypopharyngeal tumour 
is pyriform sinus. We have a good number of posterior pharyngeal wall 
cases. In Jones & Stell Liverpool study series, post cricoids carcinoma 
cases are almost equal to PF tumours. The Liverpool series also included 
cervical oesophagus growth which accounted for 7% of cases.  
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ASSOCIATION OF SMOKING AND ALCOHOL 
Study S+A+ S+A- S-A+ S-A- 
Hashibe & 
Brennan 
study(2007) 
70% 16% 10% 4% 
Present study    57%             
 
26% 2% 15% 
 
 From our study, alcohol as an independent risk factor is seen in 2% 
of cases as  compared to 10% of  cases in Brennan study36. William J Blot 
and Joseph K Mc Laughlin (1988) published an article in American 
association of cancer Research, showing that smoking and alcohol 
drinking together causes 75% of oropharyngeal cancers35.  Similar results 
found in our study.  
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STAGE OF PRESENTATION 
NASOPHARYNGEAL 
CANCERS 
N0 N1 
John Kong Sangwoos study 25% 75% 
Present study 7% 93% 
 
 In both the studies, patients predominantly present with neck 
nodes.  
OROPHARYNGEAL 
CANCERS 
Stage 
I 
II III IV N0 N1 
Mac Kregars(1995)33 7% 17% 24% 52% 40% 60% 
Present study 3% 12% 37% 48% 27% 73% 
 
 Mac Kregar, Hilgers(1995) conducted a nation wide study of 
epidemiology, treatment and survival of oropharyngeal carcinoma in 
Netherlands. The results of both the studies are almost similar. Most of 
the oropharyngeal cancers are advanced at presentation. 
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LARYNGEAL CANCERS N0 N1 
Martin A Birchall study 41% 59% 
Present study 78% 22% 
 
 As compared to Martin Study, most of the laryngeal cancers in our 
study presents with N0 neck which becomes important in treatment and 
survival of the patient.  
HYPOPHARYNGEAL CANCERS N0 N1 
Jones % Stell Liverpool series 55% 45% 
Present study 44% 56% 
 
 Hypopharyngeal cancers are advanced at presentation in most of 
the studies and carries poor prognosis.  
HISTOLOGY – SQUAMOUS CELL CARCINOMA 
STUDY ORO LAR HYPO 
MMTR 87.5% 89% 91% 
PRESENT 
STUDY 
96% 100% 97% 
 
 As in the above 2 and many other studies squamous cell carcinoma 
is the most common type of carcinoma in head and neck malignancies. 
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CONCLUSION 
 From our analysis of 150 newly diagnosed cancer cases in our 
department, we found various results from our study are almost similar to 
many National and International studies. Smoking and alcohol once again 
proves to be an important risk factor in the etiopathogenesis of  head and 
neck cancer.  Since smoking and alcoholic habits continues to rise and its 
incidence is rising among females too. Various  programs and 
counsellings are needed to educate the people especially in developing 
countries,  about the ill effects of smoking and alcohol. In India, 
education is also directed towards untoward effects of betal chewing and 
pan parag usage, which is commonly associated with oropharyngeal 
cancers. Preventive measures of these risk factors will play a vital role in 
reducing the incidence of  cancer.  
 Most of the cases are advanced at presentation. Cancer education 
should  be aimed at screening the patients early,  to have an early 
diagnosis and treatment which will improve the overall 5 - year survival 
rate of the patients. We are able to diagnose many glottis cancers early 
and most of the cases responded well to radiotherapy treatment. Glottis 
cancers are one among the very few cancers, having a good prognosis if 
detected early.  
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 In the present era, future studies should analyse the genetic and 
molecular basis of cancer which can play a vital role in cancer treatment. 
More and more understanding of the pathogenesis of cancer will help in 
the treatment and the future is towards non surgical management of 
cancers.  
 PROFORMA 
 
STUDY ON ENT MALIGNANCIES – THEIR INCIDENCE, 
PRESENTATION, ETIO – PATHOGENESIS, TREATMENT AND 
ASSOCIATION WITH NECK SECONDARIES IN THE 
DEPARTMENT OF ENT.  
GOVERNMENT  ROYAPPETTAH HOSPITAL AND KILPAUK 
MEDICAL COLLEGE HOSPITAL. 
     CASE SHEET 
GENERAL INFORMATION 
• NAME       
• AGE      
• SEX     - 
• OCCUPATION   - 
• ADDRESS    -  
• PHONE NO.    - 
• SOCIO ECONOMIC STATUS - 
 
HISTORY 
PRESENTING COMPLAINTS 
• DIFFICULTY IN SWALOWING    -  YES  /  NO 
DURATION: 
FOR SOLIDS/LIQUIDS/BOTH 
PROGRESSION: 
• DIFFICULTY  IN  BREATHING   - YES  /  NO 
DURATION: 
 
 
 PROGRESSION: 
STRIDOR      -  YES  /  NO 
• CHANGE IN VOICE       YES  /  NO 
DURATION: 
PROGRESSION: 
• NECK SWELLING     -  YES  /  NO 
DURATION: 
PROGRESSION: 
• MASS IN ENT        YES  /  NO 
DURATION: 
• LOSS OF WEIGHT     - YES  /  NO 
• LOSS OF APPETITE       YES  /  NO 
 
PERSONAL HISTORY 
• SMOKING      - YES  /  NO 
TYPE: 
NO.OF.YEARS 
QUANTITY: 
 
• ALCOHOL       YES  /  NO 
TYPE 
NO.OF.YEARS 
QUANTITY: 
• PAN PARAG     - YES  /  NO 
 
 
 IF YES DURATION: 
• DIETARY HABITS 
VEG / NON VEG 
IF NON VEG      PREFERENCE 
& FREQUENCY 
• HEAD PHONE USAGE     YES  /  NO 
• EXPOSURE TO LOUD SOUND  - YES  /  NO 
• EXPOSURE TO RADIATION   - YES  /  NO
  
• EXPOSURE TO CHEMICALS  - YES  /  NO 
• EXPOSURE TO FUMES   - YES  /  NO 
• PREVIOUS DRUG USAGE   - YES  /  NO 
• SPEAKING IN LOUD VOICE   - YES  /  NO 
• GERD      - YES  /  NO 
• OBESITY       YES  /  NO 
• STRESS       YES  /  NO 
• FAMILY H/O MALIGNANCY  - YES  /  NO 
 
PHYSICAL EXAMINATION 
• HEIGHT     - 
• WEIGHT     - 
• BP      -  
• PULSE     - 
• TEMPERATURE    - 
• PULSE RATE    - 
 
 
 GENERAL EXAMINATION 
• PALLOR     - 
• CYANOSIS     - 
• ICTERUS     - 
• BREATH  DIFF.OEA   - 
• CLUBBING     
• LYMPHADENOPATHEIS  - 
• DIETARY DEFICIENCY  - 
 
ENT EXAMINATION 
EXAMINATION OF THE ORAL CAVITY 
BUCCAL MUCOSA 
DENTITION 
EXAMINATION OF OROPHARYNX 
 
EXAMINATION OF NASOPHARYNX 
BY POST NASAL EXAMINATION 
 
EXAMINATION OF LARYNGOPHARYNX 
BY INDIRECT LARYNGOSCOPY 
 
EXAMINATION OF NOSE 
ANTERIOR RHINOSCOPY 
POSTERIOR RHINOSCOPY 
 
 
 EXAMINATION OF THE EAR 
 
EXAMINATION OF THE NECK 
 
PROVISIONAL DIAGNOSIS 
 
 
 
INVESTIGATIONS 
• HEMATOLOGICAL 
• RADIOLOGICAL 
• BIOPSY REPORT 
 
STAGING 
 
TUMOR BOARD   NUMBER   
 POLICY 
 
TREATMENT UNDERTAKEN 
 
 
 MASTER CHART 
 
S. 
No Name Age Sex Presenting Illness 
Risk 
Factors Site & Subsite 
T  
Staging 
N  
Staging Stage Histology Treatment 
1 MALLIGA 30 F CHANGE IN 
VOICE 
S-A- LAR/GLOT T1 b N 0  I PDSCC CHEMO RT 
2 ARUMUGAM 55 M SWAL 
DIFF.A,BREATH  
DIFF./STR,CHANG
E IN VOICE 
S+A+ LAR/SUB T4 N 0  IV WDSCC      TL/ 
POST 
OP RT 
3 MURALI 46 M CHANGE IN 
VOICE 
S+A+ LAR/GLOT T4 N 0  IV WDSCC TL/ 
POST OP RT 
4 RANGANATHAN 50 M SWAL 
DIFF.A,CHANGE 
IN VOICE 
S+A+ HYPO/PS T3 N 2 a IV MDSCC CHEMO RT 
5 APPAVU 75 M NS S+A- HYPO/PS T3 N 2 c IV MDSCC RT 
6 POONGAVANAM 65 M SWAL 
DIFF.A,CHANGE 
IN VOICE 
S+A+ LAR/SUP T3 N 0  III MDSCC CHEMO RT 
7 SELVARAJ 44 M EAR 
PAIN,DISCHARGE, 
HARD 
OFHEARING 
S-A- RIGHT 
MIDDLE EAR 
T2 N 0  II WDSCC RT 
8 RASHIYA 
KATHOOR 
55 F SWAL DIFF.A,NS S-A- ORO/SP T2 N 0  III PDSCC RT 
9 AMEER 58 M SWAL DIFF.A,NS S+A- ORO/SP T1 N 1 III MDSCC RT 
10 SUBRAMANIAM 60 M SWAL DIFF.A,NS S+A+ ORO/ANT T3 N 2 b IV MDSCC RT 
11 RAJENDRAN 52 M SWAL 
DIFF.A,CHANGE 
IN VOICE 
S+A+ ORO/ANT-
VAL 
T3 N 1 III MDSCC CHEMO RT 
 
 
 
 
 
 S. 
No Name Age Sex Presenting Illness 
Risk 
Factors Site & Subsite 
T  
Staging 
N  
Staging Stage Histology Treatment 
12 ARUMUGAM 52 M SWAL 
DIFF.A,BREATH  
DIFF./STR,CHANG
E IN VOICE,NS 
S+A+ ORO/ANT-
VAL 
T4 N 2 c IV MDSCC CHEMO RT 
13 ENGIAH 45 M SWAL 
DIFF.A,BREATH  
DIFF. 
S+A- ORO/LAT T2 N 0  II MDSCC CHEMO RT 
14 THIRUNAVUKAR
ASU 
54 M SWAL DIFF.A S+A+ ORO/LAT T3 N 2 c IV MDSCC CHEMO RT 
15 KULASEKARAN 70 M SWAL 
DIFF.A,BREATH  
DIFF.,CHANGE IN 
VOICE 
S+A+ ORO/ANT T3 N 2 c IV WDSCC CHEMO RT 
16 KANYAKUMARI 53 F SWAL 
DIFF.A,BREATH  
DIFF. 
S-A- ORO/ANT T3 N 0  IV MDSCC CHEMO RT 
17 KRISHNAN 65 M SWAL 
DIFF.A,CHANGE 
IN VOICE,NS 
S+A+ ORO/LAT T4 N 1 IV MDSCC CHEMO RT 
18 PAKKIRISAMY 53 M SWAL DIFF.A S+A+ HYPO/PS T1 N 2 b IV MDSCC CHEMO RT 
19 VENKATESAN 41 M SWAL DIFF.A S+A+,OR - 
PAN  
ORO/LAT T1 N 1 II MDSCC CHEMO RT 
20 BABU 66 M SWAL 
DIFF.A,BREATH  
DIFF.,CHANGE IN 
VOICE 
S+A+ HYPO/PS T3 N 3 IV MDSCC CHEMO RT 
21 LOGU 70 M SWAL 
DIFF.A,CHANGE 
IN VOICE,NS 
S+A+ ORO/ANT T3 N 2 c  IV MDSCC CHEMO RT 
 
 
 
 
 
 S. 
No Name Age Sex Presenting Illness 
Risk 
Factors Site & Subsite 
T  
Staging 
N  
Staging Stage Histology Treatment 
22 VIJAYAN 35 M SWAL 
DIFF.A,CHANGE 
IN VOICE,NS 
S+A+,OR - 
PAN  
ORO/ANT T1 N 2 c IV MDSCC CHEMO RT 
23 KALIAMURTHY 55 M SWAL 
DIFF.A,BREATH  
DIFF.,CHANGE IN 
VOICE,NS 
S+A+ HYPO/PS T4 N 2 b IV MDSCC RT 
24 VELUCHAMY 76 M SWAL DIFF.A S+A- ORO/ANT T3 N 1 III MDSCC RT 
25 VAIDHYALINGA
M 
65 M SWAL 
DIFF.A,CHANGE 
IN VOICE 
S+A- ORO/ANT T3 N 0  III LOW 
GRADE 
MC 
RT 
26 ARUMUGAM 48 M SWAL 
DIFF.A,BREATH  
DIFF. 
S+A+,OR - 
PAN,BETA
L  
ORO/LAT T3 N 1 III MDSCC CHEMO RT 
27 KANNAYAN 73 M SWAL DIFF.A S+A+ ORO/ANT T4 N 2 c IV PDSCC RT 
28 MANI 52 M SWAL 
DIFF.A,CHANGE 
IN VOICE 
S+A+, OR - 
BETAL  
ORO/ANT T3 N 0  III PDSCC CHEMO RT 
29 DAMODHARAN 65 M SWAL 
DIFF.A,BREATH  
DIFF.,CHANGE IN 
VOICE 
S+A+ ORO/ANT T3 N 3 IV PDSCC RT 
30 KATHIRVEL 70 M SWAL 
DIFF.A,BREATH  
DIFF.,CHANGE IN 
VOICE 
S+A+ HYPO/PS T4 N 2 IV PDSCC RT 
31 CHEMBAN 67 M SWAL 
DIFF.A,CHANGE 
IN VOICE 
S+A+,OR - 
PAN 
HYPO/PS T4 N 0  IV  MDSCC RT 
 
 
 S. 
No Name Age Sex Presenting Illness 
Risk 
Factors Site & Subsite 
T  
Staging 
N  
Staging Stage Histology Treatment 
32 RANJITHAM 65 F SWAL 
DIFF.A,BREATH  
DIFF.,NS 
S-A-,OR - 
BETAL  
LAR/SUP T4 N 1 IV MDSCC CHEMO RT 
33 RANGANATHAN 55 M SWAL 
DIFF.A,CHANGE 
IN VOICE 
S+A+ LAR/SUP T3 N 0  III MDSCC CHEMO RT 
34 MURUGESAN 70 M SWAL 
DIFF.A,CHANGE 
IN VOICE 
S+A- ORO/LAT T3 N 1 III MDSCC CHEMO RT 
35 ALAGESAN 17 M NS S-A- NASO T4 N 1 IV UNDIFF 
CA 
CHEMO RT 
36 RAGHUPATHY 61 M SWAL DIFF.A S+A+ HYPO/PP T3 N 0  III WDSCC RT 
37 MANICKAM 61 M SWAL 
DIFF.A,BREATH  
DIFF.,CHANGE IN 
VOICE 
S+A- LAR/SUP T3 N 1 III MDSCC RT 
38 RAVIKUMAR 45 M SWAL DIFF.A S-A- HYPO/PS T3 N 0  III SRC CHEMO RT 
39 RADHA 55 F SWAL DIFF.A S-A-,OR - 
BETAL 
LAR/SUP T4 N 0  IV MDSCC CHEMO RT 
40 KRISHNAN 67 M SWAL 
DIFF.A,BREATH  
DIFF.,CHANGE IN 
VOICE 
S+A+ LAR/SUP T3 N 0  III PDSCC RT 
41 KABIR 51 M CHANGE IN 
VOICE 
S+A- LAR/SUP T3 N 1 III MDSCC RT 
42 BHASKAR 62 M CHANGE IN 
VOICE 
S-A-  LAR/GLOT T1 a N 0  I PDSCC RT 
43 AKAMBARAM 61 M SWAL 
DIFF.A,BREATH  
DIFF.,CHANGE IN 
S+A+ LAR/GLOT T1 b N 0 I WDSCC RT 
 
 
 S. 
No Name Age Sex Presenting Illness 
Risk 
Factors Site & Subsite 
T  
Staging 
N  
Staging Stage Histology Treatment 
VOICE 
44 KUTTIAH 72 M CHANGE IN 
VOICE 
S+A- ORO/ANT T3 N 1 III PDSCC RT 
45 SURYANARAYAN
AN 
62 M BREATH  
DIFF.,CHANGE IN 
VOICE 
S+A- HYPO/PS T4 N 3 III MDSCC CHEMO RT 
46 JALENDRAN 50 M BREATH  
DIFF./STR,CHANG
E IN VOICE 
S+A+ LAR/SUP T4 N 0  IV PDSCC CHEMO RT 
47 MOHAIDEN 15 M NASAL SYM S-A- NASO T1 N 1 II NON KER 
SCC 
CHEMO RT 
48 LAZAR 72 M SWAL DIFF.A S+A- ORO/ANT T3 N 0  III PDSCC RT 
49 SANKAR 74 M SWAL 
DIFF.A,CHANGE 
IN VOICE 
S+A+ ORO/ANT T4 N 2 b IV MDSCC RT 
50 PETER 50 M SWAL DIFF.A S+A+ ORO/LAT T2 N 0  II MDSCC CHEMO RT 
51 GANAPATHY 76 M BREATH  
DIFF./STR,CHANG
E IN VOICE 
S+A- LAR/SUP T3 N 0  III MDSCC RT 
52 BALU 63 M SWAL DIFF.A S+A- LAR/SUP T3 N 1 III MDSCC CHEMO RT 
53 MAGARAJAN 50 M BREATH  
DIFF.,CHANGE IN 
VOICE 
S+A+ HYPO/PS T4 N 0  IV MDSCC RT 
54 VENGIAH 48 M SWAL DIFF.A S+A+ ORO/SP T3 N 1 III MDSCC CHEMO RT 
55 VISUVASAM 46 M SWAL 
DIFF.A,BREATH  
DIFF.,CHANGE IN 
VOICE 
S+A+ HYPO/PS T3 N 0  III WDSCC CHEMO RT 
 
 
 S. 
No Name Age Sex Presenting Illness 
Risk 
Factors Site & Subsite 
T  
Staging 
N  
Staging Stage Histology Treatment 
56 BALU 60 M BREATH  
DIFF.,CHANGE IN 
VOICE 
S+A+ LAR/GLOT T2 N 0  II MDSCC CHEMO RT 
57 RAGAVAN 50 M BREATH  DIFF. S+A+ ORO/LAT T2 N 1 III MDSCC CHEMO RT 
58 VELLAIYAN 39 M CHANGE IN 
VOICE 
S+A+ LAR/GLOT T1 N 0  I WDSCC RT 
59 RAJA 61 M SWAL DIFF.A S+A+ ORO/ANT T1 N 0  I MDSCC RT 
60 MUTHUCHAMY 72 M SWAL DIFF.A S+A+ ORO/LAT T2 N 0  II MDSCC CHEMO RT 
61 APPAYA 67 M NS S+A- ORO/LAT T2 N 3 IV MDSCC CHEMO RT 
62 MANI 58 M SWAL 
DIFF.A,CHANGE 
IN VOICE 
S+A+ LAR/SUP T3 N 3 IV WDSCC CHEMO RT 
63 UVARAJ 51 M SWAL DIFF.A,NS S+A+ ORO/LAT T1 N 1 III MDSCC CHEMO RT 
64 PAPPAMMAL 60 F SWAL DIFF.A S-A- HYPO/PP T4 N 0  IV PDSCC CHEMO RT 
65 MOHANA 
SUNDARAM 
52 M SWAL 
DIFF.A,BREATH  
DIFF.,CHANGE IN 
VOICE 
S+A+ LAR/SUP T3 N 0  III MDSCC CHEMO RT 
66 GOVINDAN 70 M SWAL 
DIFF.A,BREATH  
DIFF.,CHANGE IN 
VOICE 
S+A- LAR/SUB T4 N 1 IV MDSCC CHEMO RT 
67 RANGANATHAN 75 M SWAL 
DIFF.A,BREATH  
DIFF./STR 
S-A- HYPO/PC T1 N 0  I MDSCC RT 
68 GOVINDACHAMY 80 M SWAL DIFF.A S+A-, OR- 
BETAL 
ORO/ANT T2 N 0  II MDSCC RT 
69 PAUL 63 M NS S-A- NASO T3 N 1 III WDSCC RT 
 
 
 S. 
No Name Age Sex Presenting Illness 
Risk 
Factors Site & Subsite 
T  
Staging 
N  
Staging Stage Histology Treatment 
70 KRISHNAN 66 M BREATH  
DIFF.,CHANGE IN 
VOICE 
S+A+ LAR/GLOT T1 N 0  I WDSCC RT 
71 ALI 50 M NS S+A+ ORO/ANT T3 N 3 IV MDSCC CHEMO RT 
72 MOHAN  47 M SWAL 
DIFF.A,CHANGE 
IN VOICE 
S+A+ HYPO/PS T3 N 2 a IV WDSCC CHEMO RT 
73 BABU 57 M SWAL 
DIFF.A,BREATH  
DIFF.,CHANGE IN 
VOICE 
S+A+ HYPO/PS T3  N 3 IV PDSCC CHEMO RT 
74 RAJAMANICKAM 48 M SWAL DIFF.A,NS S+A+ ORO/ANT T4 N 2 b IV WDSCC CHEMO RT 
75 ARUMUGAM 51 M SWAL 
DIFF.A,CHANGE 
IN VOICE 
S+A+ ORO/LAT T2 N 0  II WDSCC CHEMO RT 
76 SAMPATH 70 M SWAL DIFF.A S+A- ORO/ANT T4 N 2 c IV WDSCC CHEMO RT 
77 NIZAMMUDIN 62 M SWAL DIFF.A,NS S-A- HYPO/PS T4 N 2 a IV MDSCC CHEMO RT 
78 SHANMUGAM 40 M SWAL 
DIFF.A,BREATH  
DIFF./STR,CHANG
E IN VOICE 
S+A+ HYPO/PS T4 N 0  IV MDSCC CHEMO RT 
79 BALAKRISHNAN 68 M BREATH  DIFF.,NS S+A+  ORO/ANT T3 N 3 III ADENO / 
CA 
CHEMO RT 
80 RAJ 53 M SWAL 
DIFF.A,CHANGE 
IN VOICE 
S+A+ HYPO/PS T4 N 1 IV WDSCC CHEMO RT 
81 PADMAVATHY 45 F NASAL SYM S-A- NASO T2 N 0  II WDSCC RT 
82 NARASIMHAN 62 M CHANGE IN 
VOICE 
S-A- LAR/GLOT T1 b N 0  I WDSCC RT 
 
 
 S. 
No Name Age Sex Presenting Illness 
Risk 
Factors Site & Subsite 
T  
Staging 
N  
Staging Stage Histology Treatment 
83 SHANMUGAM 48 M SWAL 
DIFF.A,CHANGE 
IN VOICE,NS 
S+A+ HYPO/PS T3 N 3 IV MDSCC CHEMO RT 
84 ANBALAGAN 58 M SWAL DIFF.A,NS S+A+ ORO/ANT T3 N 1 III WDSCC CHEMO RT 
85 SEENIVASAN 38 M SWAL DIFF.A S-A+ ORO/LAT T2  N 0 II WDSCC CHEMO RT 
86 CHELLIAH 64 M SWAL 
DIFF.A,BREATH  
DIFF./STR 
S+A- LAR/GLOT T3 N 0  III MDSCC CHEMO RT 
87 SRINIVASAN 14 M NS S-A- NASO T2 N 1 III MDSCC CHEMO RT 
88 ANWARUDDIN  76 M SWAL DIFF.A S+A- ORO/SP T3 N 2 c IV MDSCC CHEMO RT 
89 PADMA 55 F SWAL 
DIFF.A,BREATH  
DIFF. 
S-A- HYPO/PC T2 N 1  III MDSCC CHEMO RT 
90 PERIYAVAN 60 M SWAL 
DIFF.A,BREATH  
DIFF.,CHANGE IN 
VOICE,NS 
S+A+ HYPO/PS T3 N 3 IV MDSCC CHEMO RT 
91 SRINIVASAN 43 M SWAL DIFF.A S+A+,OR - 
PAN 
ORO/LAT T3 N 2 c IV WDSCC CHEMO RT 
92 KARUPPAYEE 63 F SWAL DIFF.A S-A-,OR - 
BETAL  
ORO/ANT T3 N 1 III MDSCC CHEMO RT 
93 PALANI 55 M SWAL DIFF.A S+A+ ORO/ANT T4 N 2 a IV WDSCC CHEMO RT 
94 DAWOOD 65 M SWAL 
DIFF.A,CHANGE 
IN VOICE 
S+A+ HYPO/PS T4 N 2 IV MDSCC CHEMO RT 
95 RAJENDRAN 49 M SWAL DIFF.A S+A+ HYPO/PS T3 N 2 b IV WDSCC CHEMO RT 
96 ANGAMMAL 60 F SWAL 
DIFF.A,CHANGE 
S-A-,OR - 
BETAL  
ORO/ANT T3 N 0  III WDSCC CHEMO RT 
 
 
 S. 
No Name Age Sex Presenting Illness 
Risk 
Factors Site & Subsite 
T  
Staging 
N  
Staging Stage Histology Treatment 
IN VOICE 
97 RAMAN 70 M SWAL DIFF.A S+A+,OR - 
PAN 
ORO/ANT T4 N 1 IV WDSCC CHEMO RT 
98 LOGANATHAN 64 M SWAL 
DIFF.A,BREATH  
DIFF./STR,CHANG
E IN VOICE 
S+A+ LAR/SUP T4 N 0  IV MDSCC RT 
99 RAJU 83 M SWAL DIFF.A S+A+ ORO/LAT T3 N 1 III WDSCC RT 
100 BHUVANAGIRI 60 M SWAL 
DIFF.A,BREATH  
DIFF.,CHANGE IN 
VOICE 
S+A+ ORO/ANT T3 N 2 b IV WDSCC CHEMO RT 
101 DHANALAKSHMI 62 F SWAL DIFF.A S-A-,OR - 
BETAL  
HYPO/PC T3 N 2 c IV MDSCC RT 
102 GOVINDHAN 71 M SWAL 
DIFF.A,CHANGE 
IN VOICE 
S+A+,OR - 
PAN,BETA
L 
LAR/SUP T3 N 0  III PDSCC RT 
103 KRISHNAN 75 M SWAL 
DIFF.A,BREATH  
DIFF./STR,CHANG
E IN VOICE 
S+A- LAR/SUP T4 N 0  IV MDSCC CHEMO RT 
104 MANICKAM 49 M SWAL 
DIFF.A,BREATH  
DIFF. 
S+A+ LAR/SUP T1 N 0  I PDSCC RT 
105 SAROJA 67 F NS S-A- LAR/SUP T1 N 2 b IV MDSCC RT 
106 LALITHA 66 F SWAL DIFF.A S-A- HYPO/PC T3 N 0  III WDSCC CHEMO RT 
107 KARPAGAVALLI 75 F SWAL DIFF.A S-A- ORO/ANT T3 N 0  III WDSCC CHEMO RT 
 
 
 
 
 S. 
No Name Age Sex Presenting Illness 
Risk 
Factors Site & Subsite 
T  
Staging 
N  
Staging Stage Histology Treatment 
108 PUNNIYAKODI 51 M SWAL 
DIFF.A,CHANGE 
IN VOICE,NS 
S+A+ ORO/ANT T2 N 3 III MDSCC CHEMO RT 
109 GANESAN 55 M SWAL 
DIFF.A,BREATH  
DIFF./STR,CHANG
E IN VOICE 
S+A+ LAR/GLOT T3 N 0  III WDSCC CHEMO RT 
110 SAMPATH 65 M CHANGE IN 
VOICE 
S-A+ LAR/GLOT T1 N 0  III WDSCC CHEMO RT 
111 MANI 60 M SWAL 
DIFF.A,BREATH  
DIFF./STR,CHANG
E IN VOICE 
S+A+ LAR/GLOT T3 N 0  III MDSCC CHEMO RT 
112 SUMATHY 35 F SWAL DIFF.A,NS S-A- ORO/LAT T2 N 1 III DLBL CHEMO RT 
113 MANI 52 M SWAL DIFF.A,NS S+A+ ORO/ANT-
VAL 
T3 N 2 IV MDSCC CHEMO RT 
114 RAMAKRISHNAN 60 M SWAL 
DIFF.A,CHANGE 
IN VOICE 
S+A- ORO/ANT-
VAL  
T2 N 2 c IV MDSCC RT 
115 GOVINDARAJ 65 M SWAL 
DIFF.A,CHANGE 
IN VOICE 
S+A+ HYPO/PP T3 N 0  III MDSCC RT 
116 PANDURANGAN 45 M SWAL 
DIFF.A,CHANGE 
IN VOICE 
S-A+, OR - 
PAN 
ORO/LAT T4 N 2 c IV WDSCC RT 
117 VEERAMMAL 60 F SWAL 
DIFF.A,CHANGE 
IN VOICE,NS 
S-A-,OR - 
BETAL 
HYPO/PC T3 N 0  III WDSCC CHEMO RT 
 
 
 
 
 
 
 S. 
No Name Age Sex Presenting Illness 
Risk 
Factors Site & Subsite 
T  
Staging 
N  
Staging Stage Histology Treatment 
118 GUNA 55 M SWAL DIFF.A S+A+ HYPO/PS T3 N 0 III MDSCC CHEMO RT 
119 KRISHNAN 64 M SWAL DIFF.A,NS S+A- ORO/LAT T3 N 3 IV MDSCC CHEMO RT 
120 YEDIAPPA 60 M SWAL DIFF.A S+A+ ORO/LAT T2 N 1 III WDSCC RT 
121 INDIRA 24 F NASAL SYM,NS S-A- NASO T2 N 2 III UNDIFF 
CA 
RT 
122 MANI 52 M CHANGE IN 
VOICE 
S+A+ LAR/GLOT T1 N 0 I WDSCC RT 
123 KANDASAMY 71 M SWAL 
DIFF.A,BREATH  
DIFF.,NS 
S+A+ HYPO/PS T3 N 0 III MDSCC RT 
124 KABIRDOSS 50 M SWAL 
DIFF.A,BREATH  
DIFF.,NS 
S+A+ LAR/GLOT T1 N 0 I WDSCC RT 
125 SUBRAMANIAN 65 M SWAL 
DIFF.A,CHANGE 
IN VOICE 
S+A+ HYPO/PP T2 N 0 II WDSCC RT 
126 SUBRAMANI 65 M SWAL DIFF.A S+A+ HYPO/PP T2 N 0 II WDSCC RT 
127 RATHINAM 58 F SWAL DIFF.A S-A- ORO/ANT-
VAL 
T2 N 1 III MDSCC CHEMO RT 
128 SELVAM 56 M SWAL 
DIFF.A,CHANGE 
IN VOICE 
S-A- ORO/ANT-
VAL 
T2 N 0  II MDSCC RT 
129 SUBRAMANIAN 60 M SWAL 
DIFF.A,CHANGE 
IN VOICE 
S+A+ ORO/ANT-
VAL 
T1 N 0 I WDSCC RT 
130 DHANAM 47 M SWAL DIFF.A S-A- ORO/ANT T3 N 2 IV WDSCC CHEMO RT 
131 NANDAGOPAL 38 M SWAL DIFF.A S+A- HYPO/PS T4 N 2 IV PDSCC CHEMO RT 
132 SAMY 75 M SWAL DIFF.A S+A- ORO/ANT T4 N 0  IV MDSCC CHEMO RT 
 
 
 S. 
No Name Age Sex Presenting Illness 
Risk 
Factors Site & Subsite 
T  
Staging 
N  
Staging Stage Histology Treatment 
133 RAJ 56 M SWAL 
DIFF.A,CHANGE 
IN VOICE 
S+A+ ORO/LAT T4 N 0 IV WDSCC CHEMO RT 
134 GOVINDASAMY 48 M SWAL 
DIFF.A,CHANGE 
IN VOICE 
S+A- ORO/ANT T4 N 2 c IV MDSCC CHEMO RT 
135 RANGANATHAN 78 M SWAL 
DIFF.A,BREATH  
DIFF.,NS 
S+A+,OR - 
PAN 
ORO/LAT T3 N 3 IV MDSCC CHEMO RT 
136 MEGAN 55 M CHANGE IN 
VOICE 
S+A+ LAR/GLOT T1 N 0  I MDSCC RT 
137 ENKIAH 50 M SWAL 
DIFF.A,BREATH  
DIFF.,NS 
S+A+ ORO/ANT T4 N 2 c IV PDSCC CHEMO RT 
138 RAVI 60 M SWAL DIFF.A S+A+ LAR/SUP T3 N 2 IV MDSCC CHEMO RT 
139 RAJENDRAN 32 M SWAL DIFF.A S-A- ORO/ANT T3 N 1 III MDSCC RT 
140 RAMANATHAN 75 M SWAL DIFF.A S+A- ORO/LAT T2 N 1 III MDSCC RT 
141 SUBRAMANI 65 M SWAL DIFF.A,NS S+A+ ORO/ANT T3 N 2 c IV MDSCC RT 
142 MAHENDRAN 46 M SWAL DIFF.A S+A+ HYPO/PS T4 N 1 IV MDSCC CHEMO RT 
143 SUBRAMANI 65 M SWAL 
DIFF.A,CHANGE 
IN VOICE,NS 
S+A+ ORO/ANT T4 N 2 b IV MDSCC CHEMO RT 
144 VENKATESAN 23 M SWAL 
DIFF.A,BREATH  
DIFF. 
S+A+ HYPO/PC T4 N 1 IV WDSCC RT 
145 PITCHAI 60 M CHANGE IN 
VOICE 
S+A+ LAR/GLOT T1 b N 0  I MDSCC RT 
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146 ELUMALAI 36 M SWAL 
DIFF.A,CHANGE 
IN VOICE,NS 
S+A+,OR - 
PAN 
HYPO/PS T3 N 3 IV MDSCC CHEMO RT 
147 SUBRAMANI 70 M SWAL DIFF.A S+A+ HYPO/PC T3 N 0 III MDSCC CHEMO RT 
148 LAKSHMI 55 F SWAL 
DIFF.A,CHANGE 
IN VOICE 
S-A- HYPO/PC T3 N 0 III MDSCC RT 
149 PAPPA 55 F SWAL DIFF.A S-A- HYPO/PC T3 N 1 III MDSCC CHEMO RT 
150 SHANMUGAM 55 M NASAL SYM,NS S+A+ NASO T3 N 2 III MDSCC CHEMO RT 
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 ABBREVATION 
M                     -   Male 
F                      -   Female 
EBV                -   Ebstein  barr  virus    
HLA     -  Human Leucocyte Antigen 
HPV     -   Human Papilloma Virus 
RT     -  Radiotherapy  
Chemo    -  Chemotherapy 
EBRT   -  External beam radiotherapy 
EAC    -  External Auditory  canal 
ICMR   -   Indian Council Of Medical Research 
DNA    -  Deoxyribonucleic Acid 
RNA    -   Ribonucleic Acid 
MC    -   Most common 
OP    -  Operation 
RR    -  Relative risk 
GA    -   General Anaesthesia 
AP    -  Anteroposterior 
PA    -   Posteroanterior         
FNAC   -   Fine Needle Aspiration Cytology 
PNS     -  Para Nasal sinuses 
PET     -   Positron Emission Tomography 
 
 
  
 
NASO    -   Nasopharynx 
ORO     -  Oropharynx 
HYPO    -   Hypopharynx 
CA      -  Carcinoma 
PF      -   Pyriform Fossa 
PP      -  Posterior pharyngeal wall 
PC      -   Post Cricoid 
SWAL DIFF.         -   Swallowing difficulty 
BREATH DIFF.  -  Breathing difficulty 
STR         -  Stridor 
NOS         -  Not Otherwise specified 
AE         -  Aryepiglottic  
SUP         -  Supraglottis 
SUB         -   Subglottis 
GLOT        -  Glottis 
S         -  Smoking 
A          -  Alcohol 
TLN          -  Total Laryngectomy 
WDSCC          -  Well differentiated squamous cell carcinoma 
MDSCC        -  Moderately differentiated squamous  
    cell carcinoma 
PDSCC        -   Poorly differentiated squamous cell carcinoma 
